IGHE and food allergy: Omalizumab, an anti-IgE monoclonal antibody approved by the Food and Drug Administration (FDA) in 2024 for IgE-mediated food allergies, binds circulating IgE and lowers the expression of high-affinity IgE receptors on effector cells, thereby facilitating desensitization [32,33].